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Abstract
Background: The aim of our work was to identify the genes specifically altered in pancreatic adenocarcinoma and especially
those that are altered early in cancer development.
Methodology/Principal Findings: Gene copy number was systematically assessed with an ultra-high resolution CGH
oligonucleotide microarray in DNA from samples of pancreatic cancer. Several new cancer-associated variations were
observed. In this work we focused on one of them, involving the reg4 gene. Gene copy number gain of the reg4 gene was
confirmed by qPCR in 14 cancer samples. It was also found with increased copy number in most PanIN3 samples. The
relationship betweena gain in reg4 gene copy number and cancer development was investigated on the human pancreatic
cancer cell line Mia-PaCa2 xenografted under the skin of nude mice. When cells were transfected with a vector allowing reg4
expression, they generated tumors almost twice larger in size. In addition, these tumors were more resistant to gemcitabine
treatment than control tumors. Interestingly, weekly intraperitoneal administration of a monoclonal antibody to reg4 halved
the size of tumors generated by Mia-PaCa2 cells, suggesting that the antibody interfered with a paracrine/autocrine
mechanism involving reg4 and stimulating cancer progression. The addition of gemcitabine resulted in further reduction,
tumors becoming 5 times smaller than control. Exposure to reg4 antibody resulted in a significant decrease in intra-tumor
levels of pAkt, Bcl-xL, Bcl-2, survivin and cyclin D1.
Conclusions/Significance: It was concluded that adjuvant therapies targeting reg4 could improve the standard treatment
of pancreatic cancer with gemcitabine.
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Introduction
Pancreatic cancer represents 2% of all new cases of cancer but
leads to 5% of all cancer deaths, with a five year survival rate of
only 4% [1]. The diagnosis is delayed because of the absence of
symptoms and lack of specific markers allowing detection at a
potentially curative stage. In the general population pancreatic
cancer carries a lifetime risk of approximately 0.5–1% [2]. Genetic
predisposition is involved because the lifetime risk of pancreatic
cancer is 4.7% for first-degree relatives of pancreatic cancer cases
and the risk of pancreatic cancer increases with each affected
family member. In addition, it can be inherited as part of a multi-
cancer syndrome but the vast majority of pancreatic cancers are
sporadic. Finally, tobacco smoking and diseases such as diabetes
and especially chronic pancreatitis predispose to pancreatic cancer
and about 10% of patients with intrapapillary mucinous
neoplasms (IPMNs) will develop pancreatic adenocarcinoma.
Genomic alterations can induce over- or under-expression of
genes, with important consequences when oncogenes or tumor
suppressor genes are involved. The genetic abnormalities that occur
in the precursor lesions [3] as well as during initiation and
progression of pancreatic cancer have been partially described
[4–7]. Indeed, comparative genomic hybridization (CGH) analyses
identified frequent gains on chromosomes 1q,3, 5, 7p,8q,11q,12p,
17q, 19q and 20q, and losses on chromosomes 3p, 6, 8p, 9p, 10q,
13q, 15q, 17p and 18q [8–13]. The aim of our work was to identify,
using an ultra-high resolutionCGH oligonucleotide microarray, the
genes specifically altered in pancreatic adenocarcinoma cells and
especially those that are altered early in cancer development.
Several candidates were identified using this approach, among
PLoS ONE | www.plosone.org 1 October 2009 | Volume 4 | Issue 10 | e7495which the reg4 gene [14] showed gene copy number gain in 14/14
analyzed samples. This is to our knowledge the first report of reg4
gene copy number gain in pancreatic cancer.
In this paper we report that the reg4 gene, positioned on
chromosome 1p13.1-p12, is present in increased copy number in
pancreatic cancer cells and in late precancerous pancreatic lesions.
Studies on a xenografted pancreatic cancer cell line showed that
reg4 over-expression stimulates tumor growth and, conversely,
that blocking circulating reg4 protein with a specific antibody
inhibits tumor growth.
Results
The reg4 gene is present in increased copy number in
pancreatic cancer cells and in PanIN 3 precancerous lesions
Using an Affymetrix microchip-based DNA scanning approach,
we identified several genes with an abnormal copy number in
DNA from pancreatic cancer cells. We first focused on genes
altered in all 14 DNA samples and found that reg4 showed
systematically increased copy number. All microarray data
reported in the manuscript is described in accordance with
MIAME Guidelines. Complete data describing other DNA
abnormalities will be published elsewhere. reg4 gene increased
copy number was particularly interesting because its expression
was previously involved in the aggressiveness of several cancers
[15–17], including pancreas [18]. Figure 1 shows the amplified
locus, which comprises the reg4 gene, in DNA from these patients.
We also monitored the copy number of reg4 in the pancreatic
precancerous lesions named PanINs. Combining a laser capture
approach and a qPCR method, we measured the number of reg4
copies in the three grades of PanIN lesions and found an increased
copy number of reg4 in 0/6, 1/7 and 6/7 of PanIN1, PanIN2 and
PanIN3 lesions, respectively (Figure 2). As control, copy numbers
of TERT (Telomerase Reverse Transcriptase) and RPP21 (RNaseP
protein p21) genes were assessed on the same DNA samples and
two copies were always found (data not shown). Altogether, these
data suggest that the reg4 gene copy number is frequently increased
in pancreatic cancer and in the last stage of precancerous lesions
(PanIN3) but rarely in earlier stages (PanIN1 and PanIN2).
reg4 overexpression stimulates cell growth and increases
resistance to gemcitabine treatment in MiaPaCa2 cells in
vitro
It was previously shown that forced reg4 overexpression in vitro
increases cell growth rate and resistance to programmed cell death
in non-pancreatic cancer-derived cells. We obtained Mia-PaCa2
cellsoverexpressing reg4 protein(Mia-PaCa2/reg4)bytransduction
ofa recombinant retrovirus (Figure 3) and analyzed their capacityto
grow and to resist to the antitumoral drug gemcitabine in vitro.W e
observed that cells expressing reg4 grew about 50% more rapidly
than Mia-PaCa2/empty cells. We confirmed that increased cell
growth was due to reg4 overexpression by knockingdown reg4 with
a specific siRNA transfection and found a loss of this capacity, as
Figure 1. The reg4 gene is found with increased copy number in pancreatic cancer. Allelic ratios were calculated with the Partek Genomics
Suite, version 6.4. HapMap (270 samples) was used to create baseline copy number. Genomic segmentation was utilized to detect copy number gain
or loss. Regions were detected using the following segmentation parameters: minimum of 10 genomic markers; segmentation p-value threshold
lower than 0.001; a signal to noise equal to 0.3. A. Schematic representation of the reg4 locus. Positions of the 7 genes present in this locus are
indicated: from left to righ: ZNF697, PHGDH, HMGCS2, REG4, NBPF7, ADAM30 and NOTCH2. B. Position of the copy number gain segment found in all
14 DNA samples from pancreatic cancer, which includes the reg4 gene. C. Genomic changes in the amplified segment of the reg4 locus, determined
by the Affymetrix Genome-Wide Human SNP Array 6.0 analysis in the 14 pancreatic cancer samples. Genetic gains are shown as red bars and losses as
blue bars, grey bars corresponding to 2 copies as indicated in the scale shown underneath. Note the predominance of gains (red) in the reg4 region.
D. Detail of gains/losses in the reg4 gene and its flanking regions for all 14 analyzed samples.
doi:10.1371/journal.pone.0007495.g001
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with50 mMgemcitabinefor48 hours,theresistancetothedrugwas
increased in cells overexpressing reg4, compared to control, but lost
in cells eventually transfected with a siRNA against reg4 (Figure 4).
These results indicate that reg4 is involved in cell growth and
resistance to anticancer drugs in pancreas cancer-derived cells as
previously suggested in non-pancreatic cells.
REG4 is a 16 kDa secretory protein. To test whether effects of
REG4 on cell growth and resistance to gemcitabine treatment were
due to its endocrine/paracrine function in pancreatic cells, we added
a specific monoclonal antibody against REG4 protein to the culture
medium, to block its activity. In these conditions, the effects of reg4
overexpression disappeared almost completely, as shown in Figure 4.
These results indicate that REG4 exerts its effects on cell growth and
resistance to gemcitabine through an endocrine/paracrine way.
reg4 overexpression increases tumorigenicity and
resistance to gemcitabine treatment
We compared the capacities of Mia-PaCa2/empty and Mia-
PaCa2/reg4 cells to form tumors after subcutaneous injection in
nude mice. As shown in Figure 5, tumors that formed from cells
over-expressing reg4 protein grew more rapidly than cells that do
not express the gene. Tumor volume was 70% larger when using
Mia-PaCa2/reg4 cells than with control Mia-PaCa2 cells.
Interestingly, when mice were treated with gemcitabine, tumors
over-expressing reg4 protein displayed increased resistance to the
treatment, compared to tumors formed with Mia-PaCa2/empty
cells. While the volume of tumors generated with Mia-PaCa2 cells
decreases by 60% after gemcitabine treatment, the volume of
reg4-expressing cells decreased by 20% only.
Systemic treatment with an antibody against reg4
decreases tumorigenicity
The next step was to analyze the effect of blocking reg4 with a
specific monoclonal antibody on the growth of tumors induced by
subcutaneous injection of Mia-PaCa2 cells. As shown in Figure 6,
treatment with the reg4 antibody decreased tumor development by
about 50%. In addition, combining reg4 antibody treatment with
gemcitabine resulted in further reduction of tumor volume.
Altogether, these results indicate that targeting reg4 protein might
be used in cooperation with gemcitabine to treat pancreatic cancer.
Intraperitoneal injection of reg4 antibody reduces the
levels of antiapototic proteins and cell cycle-associated
proteins in Mia-PaCa2-induced tumors
Because systemic treatment with the antibody reduces tumor growth
and increases sensitivity to gemcitabine treatment, we used western blot
analysis to monitor in tumors the influence of reg4 antibody treatment
on the intracellular levels of proteins associated with apoptosis
Figure 2. reg4 gene amplification in pancreatic cancer and precancerous lesions measured by quantitative PCR. Homogeneous
populations of cells were carefully microdissected using a Laser Capture Microdissection System. PanINs were graded 1 to 3 as a function of the
importance of architectural and cytological abnormalities. DNA from pancreatic cancer samples obtained by endoscopic ultrasound (EUS)-guided fine
needle aspiration was used. DNA from blood leucocytes was used as control. reg4 gene copy number was determined by qPCR performed in
triplicate and results were analyzed using the RealQuant software.
doi:10.1371/journal.pone.0007495.g002
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D1). As expected levels of phosphorylated AKT, Bcl-2, Bcl-xL and
survivin were significantly reduced in tumors from mice treated with
the reg4 antibody compared to control. Level of cyclin D1 was also
found reduced in reg4 antibody-treated mice (Figure 7). These findings
probably account for the observed reduced growth rate.
Discussion
In this study, our hypothesis was that early genomic abnormalities
occurring in pancreatic cancer cells are responsible for the bad
prognosis of the patients and for the lack of adequate responseto anti-
cancer drugs, including gemcitabine. Several DNA regions with
altered gene copy number were indeed observed in tumors from
patients without detectable metastases at the time of the study. In the
present work, we focused our attention on the chromosome region
containing the reg4 gene because it showed increased copy number in
all 14 patients analyzed. In addition, an increased copy number of
this region was also found in almost all PanIN3, the latest stage of
precancerous pancreatic lesions, suggesting that reg4 gene amplifica-
tion is an early event in pancreatic cancer development. reg4 is a
small secreted protein that contains a single well conserved
carbohydrate-recognition domain [14,15]. reg4 is a member of a
multigenic family named reg (reviewed in 19). In humans, five
structurally-related members have been identified to date and
grouped into three subclasses based on the primary structures of
the encoded proteins namely REG1A and REG1B (Type 1),REG3A
and REG3G (Type 3) and REG4 (Type 4). Contrary to reg1A, reg1B,
reg3A and reg3G genes, all located on chromosome 2p12, reg4 is on
chromosome 1p13.1-p12. Several reports in the literature suggest a
major role for REG4 in cancer. For example, REG4 expression
seems to be responsible for cell resistance to anticancer drugs such as
5-fluouracil and methotrexate [15,20], it promotes AKT phosphor-
ylation and over-expression of the antiapoptotic proteins Bcl-2, Bcl-
xL and survivin [21,22], it activates the EGF receptor/Akt/AP1
signaling pathway [21] and its expression correlates with enhanced
peritonealmetastasisingastriccarcinomas[22,23].It issystematically
overexpressed in cancerous tissues derived from colon [15,24],
stomach [16], prostate [25] and pancreas [18] and in diseases
predisposing to colon cancer such as ulcerative colitis [14,26],
Crohn’s disease [14] and colorectal adenoma [24]. The early
amplification of its gene in pancreatic cancer described in this study
(Figures 1 and 2) and its oncogenic activity reported in the literature
prompted us to further study the role of REG4 in pancreatic
tumorigenicity and in resistance of pancreatic cancer to gemcitabine
treatment. The first observation was that pancreatic cancer-derived
cells overexpressing REG4 protein grew more rapidly and weremore
resistant to gemcitabine treatment (Figure 4). The second, more
important observation was that, in a xenograft model, tumors
induced with Mia-PaCa2 cells expressing reg4 grew more rapidly
than control tumors, obtained with native Mia-PaCa2 cells (Figure 5).
In addition, we found that the tumors induced by Mia-PaCa2 cells
expressing reg4 were more resistant to gemcitabine treatment than
control tumors, in agreement with in vitro data and previous reports
suggesting the involvement of REG4 in cell resistance to anticancer
drugs [15,20] and response to chemoradiotherapy [27]. The third,
very exciting result was obtained when mice with Mia-PaCa2-
induced tumors were treated with systemic administration of a
specific anti-reg4 antibody (Figure 6). We observed an important
reduction in tumor size and an increased sensitivity to gemcitabine
treatment in mice given once a week anti-reg4 antibody. Because the
limited efficiency of pancreatic cancer treatment with gemcitabine
might be due to the presence of stroma in tumors [28], we looked
whether reg4 overexpression influenced the extent of stroma
formation in subcutaneously xenografted Mia-PaCa2 cells. Semi-
quantitative analysis revealed no significant difference between
tumors overexpressing or not REG4, or treated with REG4antibody,
all of them showing very limited stroma (data not shown). However,
our results couldbe explained, at leastin part, by the fact that levels of
the antiapoptotic-associated proteins such as activated AKT, Bcl-2,
Bcl-xL and surviving, as well as the cell cycle-associated protein cyclin
D1, were strongly decreased (Figure 7) indicating that apoptosis and
cell cycle are regulated by reg4. Because antibodies are not supposed
to penetrate tumor cells in large amounts, an autocrine or paracrine
effect must be considered. Upon secretion by tumor cells, reg4 would
activate, probably through specific receptors, intracellular pathways
that favor cancer progression. These data are in agreement with
results found in colon and gastric cancer cells in vitro [21,22].
Altogether, these results suggest that overexpression of the REG4
protein, induced by its early gain in gene copy number, plays a major
role in pancreatic tumor development and resistance to anticancer
drugs. Targeting circulating REG4 protein appears as a promising
adjuvant to current therapies of pancreatic adenocarcinoma, based
on gemcitabine administration.
Materials and Methods
Study of the reg4 gene copy number in pancreatic cancer
Fourteen consecutive pancreatic cancer samples were obtained by
endoscopic ultrasound (EUS)-guided fine needle aspiration cytology
between June 2007 and September 2007 at the Hospital Nord,
Marseille. Written informed consent was obtained from all partici-
Figure 3. Overexpression of the REG4 protein in Mia-PaCa2
cells. The entire coding sequence of the reg4 cDNA was subcloned into
the pLPCX retroviral vector. Phoenix Amphotropic packaging cells were
transfected with the retroviral plasmid to obtain the supernatant
containing retroviral particles. Target Mia-PaCa2 cells were plated in the
presence of the supernatant containing retroviral particles as described
in the Material and Methods section. The populations of reg4-
expressing Mia-PaCa2 (Mia-PaCa2/reg4) and control cells (Mia-PaCa2/
empty), infected with the empty vector, were isolated by puromycin
selection. Expression of REG4 was measured by western blot on cell
extracts, using the anti-reg4 monoclonal antibody. After development,
the membrane was stripped and re-probed for b-actin.
doi:10.1371/journal.pone.0007495.g003
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metastasis whereas 8 presented with metastases at the time of the
p u n c t i o n .D N Aw a se x t r a c t e d ,a m p l i fied and hybridized on Affymetrix
Genome-Wide human SNP array 6.0 according to the manufacturer’s
instructions (Affymetrix Inc.). The Affymetrix Genome-Wide Human
SNP Array 6.0 features more than 1.8 million markers of genetic
variation, including more than 906,600 single nucleotide polymor-
phisms (SNPs) and more than 946,000 probes for the detection of copy
number variation. The median inter-marker distance taken over all 1.8
million SNP and copy number markers combined is 696 bases. The
array also contains 202,000 probes targeting 5,677 known regions of
copy number variation, resolve into 3,182 distinct, non-overlapping
segments, from the Toronto Database of Genomic Variants.
Hybridization, washing, staining, and chip scanning were performed
by the CRCHUL microarray Core Facility using materials and
methods provided by the manufacturer (Affymetrix Inc.).
Overall hybridization quality was estimated by the call rate
index obtained from GeneChip Genotyping Analysis Software
(GTYPE, birdseed algorithm using default parameter settings).
Allelic ratios were calculated with the Partek Genomics Suite,
version 6.4 (Partek Inc., St. Louis, MO) using the proprietary
default parameters. A 270 HapMap samples was used to create
copy number from baseline. Genomic segmentation was utilized as
a method to detect copy number alterations. Regions were
detected using the following segmentation parameters: minimum
of 10 genomic markers; segmentation p-value threshold lower than
0.001; and a signal to noise equal to 0.3. Using these parameters,
10263 segments were detected. Selected segments were visualized
in a genomic context with the PartekH Genomics Suite.
DNA from PanIN lesions
Seven micron sections from formalin-fixed, paraffin embedded
tissue blocks were stained with hematoxylin and eosin. Homoge-
neous populations of cells were carefully microdissected using a
PixCell II Laser Capture Microdissection System (Arcturus,
Mountain View, CA) according to the manufacturer’s instructions.
PanINs were graded 1 to 3 according to current recommendations
(http://pathology.jhu.edu/pancreas_panin/ and [29]) as a function
of the importance of architectural and cytological abnormalities.
Seven human pancreatic samples were analyzed in which we
systematically found PanIN2 and PanIN3 lesions but PanIN1
lesions were found in only 6 of them. A total of .300 cells was
collected for each category from serial tissue sections. Collected cells
weretransferred to an Eppendorf tubeand resuspended in20–50 ml
of lysis buffer containing 10 mM Tris, 1 mM EDTA, 0.5% Tween
20 (pH 8.3), and 5 ml of proteinase K (20 mg/ml). Samples were
incubated 24 hours at 55uC followed by boiling for 10 min to
inactivate proteinase K. DNeasy Tissue Kit (Qiagen) was used to
extract DNA according to the manufacturer’s protocol. Extracted
DNA was quantified using a NanoDrop ND-1000 spectrophotom-
eter (Nano-Drop Technologies, Wilmington, DE).
reg4 gene copy number estimation by Real-Time PCR
reg4 gene copy number was determined using the hreg4-F: 59-
TTTACTCCCTGTGGTCTGGG-39 and hreg4-R: 59-CTCTT-
TTCTCCAGCAAGGCA-39 primers. Amplification was per-
formed in a LigthCycler 480 (Roche Diagnostic) using the
following schedule: 10 s denaturation at 95uC, 45 cycles of 8 s
denaturation at 95uC, 7 s annealing at 60.5uC and 14 s of
Figure 4. Influence of a reg4 siRNA or a REG4 antibody on growth and response to gemcitabine of Mia-PaCa2 cells overexpressing
REG4. Mia-PaCa2/reg4 and Mia-PaCa2/empty cells were transfected with a specific siRNA against reg4 (A) or incubated in the presence of an anti-
REG4 monoclonal antibody (B) and their growth and their resistance to gemcitabine treatment was measured by the MTS assay. Results were
expressed as percent of untreated Mia-PaCa2/empty cells.
doi:10.1371/journal.pone.0007495.g004
reg4 in Pancreatic Cancer
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20uC/s to 95uC, cooling at 20uC/s to 65uC and heating at 0.1uC/s
to 95uC with fluorescence data collection at 0.1uC intervals.
Standard curves were generated using a 10-fold dilution series
ranging from 0.1 ng to 100 ng. We performed qPCR for each
individual in triplicate and determined the normalized relative
copy number by generating a standard curve and normalizing
across samples. PCR results were analyzed using the RealQuant
software (Roche Diagnostic). The same 14 DNA samples from
pancreatic cancer used for hybridization on the Affymetrix
Genome-Wide human SNP array 6.0 were used for qPCR.
DNA from blood leucocytes obtained from apparently healthy
individuals was used as control.
Retroviral vector and retroviral-mediated gene transfer
The entire coding sequence of reg4 cDNA was amplified by
PCR using the primer pair 59-GGGAATTCATGGCTTCCA-
GAAGCATGCGG-39 (forward) and 59-GGCTCGAGCTA-
TGGTCGGTACTTGCACAGG-39 (reverse), which contained
EcoRI and XhoI restriction sites (underlined). The product was
subcloned into EcoRI-XhoI restriction sites of the pLPCX
retroviral vector obtained from S. Lowe (Cold Spring Harbor
Laboratory, NY). Phoenix Amphotropic packaging cells (10
6) were
plated in a six-well plate, incubated for 24 h and transfected with
polyethyleneimine with 5 mg of retroviral plasmid. Forty-eight
hours later, the medium containing the virus was filtered (0.45 mm
filter, Millipore) to obtain the first supernatant. Target Mia-PaCa2
were plated at 2610
5 cells per 35-mm dish and incubated
overnight. For infection, the culture medium was replaced by an
appropriate mix of the first supernatant and culture medium (v/v),
supplemented with 4 g/ml polybrene (Sigma), and cells were
incubated at 37uC. The population of reg4-expressing Mia-PaCa2
(Mia-PaCa2/reg4) was isolated by selection in the presence of
puromycin (1 mg/ml). Mia-PaCa2 infected with the empty vector
(Mia-PaCa2/empty) was used as control.
in vitro studies
Cell culture conditions and siRNA transfection. The
pancreatic cancer cell lines Mia-PaCa2/reg4 and Mia-PaCa2/
empty were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum and 2 mM
L-glutamine in a humidified 5% CO2 atmosphere. The day before
siRNA transfection, cells were plated in 6-well plates to eventually
give 30–50% confluence. After removal of the medium, cells were
washed once with serum-free medium and transfection was done
in serum-free medium by addition of a mix composed of 10 ml
Oligofectamine Reagent (Invitrogen) and 200 pmoles siRNA (reg4
siRNA [59CTTCAGGAAGCTGAGGAAC39] or control siRNA
[59AATTCTCCGAACGTGTCACGT39] targeted sequences)
diluted in 240 ml serum-free medium. After an incubation period
of 4 hours at 37uC, the transfection medium containing siRNAs
was replaced by fresh medium.
Figure 5. Growth and response to gemcitabine of xenografted
Mia-PaCa2 cells overexpressing REG4. Approximately 2610
6 Mia-
PaCa-2 cells were inoculated subcutaneously with 0.1 ml of Matrigel to
nude mice. Gemcitabine (100 mg/kg) was injected intraperitoneally
twice a week. Tumor dimensions were measured once weekly and tumor
volumes calculated with the formula length 6width 6depth 60.5236.
Values are expressed as the mean +/2 SE of six measurements.
doi:10.1371/journal.pone.0007495.g005
Figure 6. Growth and response to gemcitabine of pancreatic
tumors treated with a specific anti-REG4 antibody. Approxi-
mately 2610
6 Mia-PaCa-2 cells were inoculated subcutaneously with
0.1 ml of Matrigel to nude mice. One day before tumoral cell inoculation,
the control group received an intraperitoneal injection of 150 ml of PBS,
whereas the assay group received 0.25 mg of reg4 monoclonal antibody
in 150 ml of PBS. Vehicle buffer or anti-reg4 antibody was injected weekly
in animals. Tumor dimensions were measured once weekly and tumor
volumes calculated with the formula length 6width 6depth 60.5236.
Gemcitabine (100 mg/kg) was injected intraperitoneally twice a week.
Values are expressed as mean +/2 SE (n=6).
doi:10.1371/journal.pone.0007495.g006
reg4 in Pancreatic Cancer
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4 cells/well
were seeded on 96-well plates in 100 ml of culture medium. The
next day, gemcitabine (purchased from Eli Lilly) was added in
100 ml of medium to a final concentration of 50 mM in the presence
or not of 1 mg of reg4 monoclonal antibody. After 48 hours, 20 ml
MTS ([3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium] reagent obtained from Promega)
was added, the plates were incubated at 37uC for 30 min, and the
absorbance read at 490 nm.
in vivo studies
Assessment of in vivo tumor growth. Institutional
guidelines for the proper and human use in research were
followed. Approximately 2610
6 Mia-PaCa-2 cells were inoculated
subcutaneously with 0.1 ml of Matrigel (BD Biosciences Discovery
Labware) to 6-week-old male nude mice. One day before tumoral
cell inoculation, the control group received an intraperitoneal
injection of 150 ml of PBS (vehicle), whereas the assay group
received 0.25 mg of reg4 monoclonal antibody in 150 mlo fP B S .
Vehicle buffer or anti-reg4 antibody was injected weekly in animals.
Tumor dimensions were measured once weekly and tumor volumes
calculated with the formula length 6 width 6 depth 60.5236 as
previously reported [30]. Gemcitabine (100 mg/kg) was injected
intraperitoneally twice a week. All studies were performed in
accordance with the European Union regulations for animal
experiments. The experiments were approved by the ethics
committee at Marseille University.
Western blot analysis. Mia-PaCa2 cells and tumor tissue
samples were lysed in a homogenization buffer containing
pepstatin (1.45 mM), leupeptin (2.1 mM), DTT, triethanolamine
(50 mM) and EDTA/EGTA (0.1 mM). Cell debris and insoluble
materials were eliminated by centrifugation (14,000 g, 30 minutes
at 4uC) and soluble fractions were either immediately assayed or
stored at 280uC until use. Total protein (50 mg) was loaded in
Laemmli buffer onto a 12.5% SDS-polyacrylamide gel in a Mini
Cell (Bio-Rad). The proteins were transferred to nitrocellulose
membranes for 1 hour using a Mini Trans-Blot Electrophoretic
Transfer Cell (Bio-Rad). The membrane was blocked in 1x PBS/
0.05% Tween 20/5% nonfat dry milk overnight at 4uC. After two
washes in 1x PBS/0.005% Tween 20, primary antibodies were
added for 1–2 hours. After three more washes, the secondary
antibody was added for 1.5 hour. The membrane was developed
using the enhanced chemiluminescence (ECL) kit (Amersham Life
Science) on Kodak film in the dark room. The membrane was
then stripped and reprobed for b-actin by using the protocol
described in the ECL kit.
Antibodies. Anti-human reg4 monoclonal antibody (Clone
200214) was purchased from R&D Systems; Bcl-2 (C21), Bcl-xL
(H-62), survivin (FL-142), cyclin D1 (C20) and b-actin (N-21)
rabbit polyclonal antibodies were from Santa Cruz Biotechnology;
phosphorylated AKT (phospho-Ser473) polyclonal antibody was
from Upstate Biotechnology Inc; pan-AKT monoclonal antibody
(clone 40D4) was from Cell Signaling Technology.
Statistical analysis. All results were expressed as mean +/2
SE. Statistical analysis was performed by a one way ANOVA
followed by Fisher’s protected least significant difference (PLSD)
test (Statview 512, Brain Power Inc., Calabases, CA). Values of
p,0.05 were considered statistically significant.
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Figure 7. Expression of phosphorylated AKT, Bcl-xL, Bcl-2,
surviving and cyclin D1 in pancreatic tumors treated with a
specific anti-REG4 antibody. Tumor tissue samples were lysed in a
homogenization buffer containing a cocktail of antiproteases. Cell
debris and insoluble materials were eliminated by centrifugation and
soluble fractions were loaded in Laemmli buffer onto a 12.5% SDS-
polyacrylamide gel. The proteins were transferred to nitrocellulose
membrane and membrane incubated with the anti phosphorylated AKT
(phospho-Ser473), anti-pan AKT, anti-Bcl-2, anti-Bcl-xL, anti-survivin or
anti-cyclin D1 antibodies. After development, the membrane was
stripped and reprobed for b-actin.
doi:10.1371/journal.pone.0007495.g007
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